Ophtimed Rx

OphtiMed Rx LTD is a preclinical ophthalmic drug development company led by experts in ophthalmology, molecular biology, biotech, out-licensing, and M & As. The company is developing a novel molecular therapy for dry Age-related Macular Degeneration (AMD), a leading cause of blindness affecting millions worldwide. Yet, no effective treatments exist to prevent retinal damage and vision loss. Our drug targets the aging process (cellular senescence) that underlies AMD, offering a transformative solution to halt the disease in its early stages and preserve vision. Our cutting-edge therapy will prevent the loss of vision and independence and bring enormous benefits to patients.